CAAT & CAT

The Chronic Airways Assessment Test (CAAT) formerly known as the COPD Assessment Test (CAT)

CAAT^TM and CAT^TM are the names for an 8-item questionnaire designed to assess the impact of disease on a person’s life (health status).

The patient-completed questionnaire can be delivered in paper format or digitally. It covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts, including physical activity, confidence, sleep, and energy.

• The CAT was developed by a multi-disciplinary group of international experts in COPD supported by GSK, and it is available to patients and healthcare providers in multiple languages at the website https://www.catestonline.org/.
  
  • The CAT has been used as a tool that helps patients and providers have a meaningful conversation when discussing the disease.
  • The CAT was also used by researchers in observational and interventional clinical trials to support the development of new treatment approaches.
  • Researchers can obtain access to the CAT (free to academic researchers and nonprofits) at https://eprovide.mapi-trust.org/instruments/copd-assessment-test.
  • In addition to its use in COPD, the CAT has been used in studies in people with asthma, bronchiectasis, and interstitial lung disease (ILD). Those studies demonstrate the potential for the CAT as a tool for use in other lung conditions.
    
• The CAAT is the same questionnaire as the CAT, with an adaptation of the introductory sentence referring to “chronic airway disease” instead of COPD to permit its application to other conditions.
  • Psychometric validation of CAAT in asthma and COPD was performed using data from the NOVELTY study¹ funded by AstraZeneca.
  • In addition to being a potential tool for clinical trials in diseases beyond COPD, for which the CAT was developed, the CAAT has the potential to be a tool used by patients living with multiple lung conditions and healthcare providers to have a conversation about their health status.
  • For application in clinical trials (free for academic researchers and nonprofits), please apply here
    https://eprovide.mapi-trust.org/instruments/chronic-airways-assessment-test

Download and use the CAAT

The CAAT form can be used only for the purpose of helping patients and clinicians.

Download the CAAT PDF in different languages

Explanatory Videos

Learn from patients and providers about the benefits of using the CAAT in practice.

The CAAT Governance Board (GB)

Our mission is to make the CAAT available to a global audience of patients, families, and healthcare providers. The Global Allergy and Airways Patient Platform (GAAPP), a global umbrella nonprofit comprised of multiple patient advocacy organizations, assumed the operational lead for the GB in November 2023.  This GB replaced the CAT governance board that was formed in 2007, managed by GSK until 2020, and then the COPD Foundation until November 2023.

The GB will focus on ensuring the CAAT scientific integrity and development strategy while working with an international Scientific and Clinical panel of experts focused on validation, dissemination, translations, and implementation of the CAAT in different lung conditions.

 Clinical and Scientific Advisory Panel 

CAAT References

1. Tomaszewski EL, Atkinson MJ, Janson C, Karlsson N, Make B, Price D, Reddel HK, Vogelmeier CF, Müllerová H, Jones PW; NOVELTY Scientific Community; NOVELTY study investigators. Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD. Respir Res. 2023 Apr 8;24(1):106 (Full text article)
2. Tamaki K, Sakihara E, Miyata H, Hirahara N, Kirichek O, Tawara R, Akiyama S, Katsumata M, Haruya M, Ishii T, Simard EP, Miller BE, Tal-Singer R, Kaise T. Utility of Self-Administered Questionnaires for Identifying Individuals at Risk of COPD in Japan: The OCEAN (Okinawa COPD casE finding AssessmeNt) Study. Int J Chron Obstruct Pulmon Dis. 2021 Jun 17;16:1771-1782. doi: 10.2147/COPD.S302259. PMID: 34168439; PMCID: PMC8216667. (Full text article)